title: Antibody profile of pregnant women with antiphospholipid syndrome and pregnancy outcome after treatment with low dose aspirin and low-weight-molecular heparin.
abstract: The aim of the research was to show our diagnostic and therapeutic experience with antiphospholipid syndrome (APS) in pregnant women. 36 pregnant women suspect on APS were included in the study: 32 with primary antiphospholipd syndrome (PAPS) and 4 with secondary antiphospholipid syndrome (SAPS). All pregnant women received low-molecular-weight-heparin (LMWH) and low dose aspirin (LDA) therapy. Control group represented 26 women with SAPS and previous bad reproductive anamnesis. Average pregnancy lasted 37.06 +/- 0.707 weeks. LMWH and LDA therapy was successful in 97.22%. Lupus anticoagulant (LA) was found to be more frequent in PAPS group (71.87%). Anticardiolipin antibodies (aCL) were found to be more frequent in SAPS (26.66%). For three patients (3.37%), PAPS was diagnosed due to a fact that they had positive antibeta2-glycoproteinl (antibeta-GP1). To make APS diagnosis, it is of great importance to search for all antiphospholipid antibodies. LMWH and low dose of acetylsalicylic acid should be the first choice therapy.
authors.affiliation: Department of Internal Medicine, School of Medicine, University of J. J. Strossmayer, Osijek, Croatia. glasnovic.marija@kbo.hr
authors.forename: Marija
authors.initials: M
authors.lastname: Glasnović
authors.forename: Ivica
authors.initials: I
authors.lastname: Bosnjak
authors.forename: Aleksandar
authors.initials: A
authors.lastname: Vcev
authors.forename: Ivan
authors.initials: I
authors.lastname: Soldo
authors.forename: Maja
authors.initials: M
authors.lastname: Kosuta
authors.forename: Bahrija
authors.initials: B
authors.lastname: Lenz
authors.forename: Elizabeta
authors.initials: E
authors.lastname: Glasnović-Horvatić
authors.forename: Silva
authors.initials: S
authors.lastname: Soldo-Butković
authors.forename: Nikola
authors.initials: N
authors.lastname: Mićunović
mesh_terms: D000328:Adult; D017153:Antibodies, Anticardiolipin / Q000097:blood*; D016736:Antiphospholipid Syndrome / Q000188:drug therapy* / Q000276:immunology; D001241:Aspirin / Q000627:therapeutic use*; D005260:Female; D006495:Heparin, Low-Molecular-Weight / Q000627:therapeutic use*; D006801:Humans; D016682:Lupus Coagulation Inhibitor / Q000097:blood*; D011247:Pregnancy; D011248:Pregnancy Complications / Q000188:drug therapy*; D011256:Pregnancy Outcome
chemical_list: D017153:Antibodies, Anticardiolipin; D006495:Heparin, Low-Molecular-Weight; D016682:Lupus Coagulation Inhibitor; D001241:Aspirin